Article Text

Download PDFPDF
Review: Adding SSRIs to antipsychotics does not improve negative symptoms in people with schizophrenia

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sepehry AA, Potvin S, Elie R, et al. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 2007;68:604–10.


Embedded ImageDesign:

Systematic review with meta-analysis.

Embedded ImageData sources:

PsycINFO, MEDLINE (1967–2005), Current Contents (1993–2005), hand searching of reference lists, and contact with pharmaceutical companies.

Embedded ImageStudy selection and analysis:

The review included randomised, placebo-controlled, double-blind trials comparing the addition of SSRIs to antipsychotics versus adding placebo in people with schizophrenia-spectrum disorder. Main exclusions: comorbid obsessive-compulsive disorder; studies of monoamine oxidase inhibitors, tricyclic, dual action, or atypical antidepressants (for example, bupropion); incomplete or unavailable data; crossover RCTs. Data were extracted by two reviewers, with disagreement resolved by consensus. Hedges’ g effect sizes (which adjust for sample size) were calculated using a random effects model. Heterogeneity was assessed using the Q statistic, with the threshold for significance set at p<0.1. In addition, …

View Full Text


  • Sources of funding: None reported.


  • Competing interests: None declared.